Alpha-2 macroglobulin gene in early- and late-onset Alzheimer disease

Neurosci Lett. 1999 Aug 20;271(2):129-31. doi: 10.1016/s0304-3940(99)00537-6.

Abstract

Alpha-2-macroglobulin (A2M) is a proteinase inhibitor that is present in senile plaques and may play a role in metabolism of amyloid beta (A beta) peptide. Recently it was reported that inheritance of the deletion allele (A2M-2) confers increased risk for late-onset Alzheimer disease (AD) with significance of this effect similar to the epsilon4 allele of apolipoprotein E (APOE). We examined the distribution of A2M genotypes and alleles in a cohort of 146 AD patients and 160 age-matched non-demented individuals. There was no evidence for association in the total sample or in subsets stratified by age or APOE epsilon4 status. These results suggest that this polymorphism is not a strong genetic risk factor for either early- or late-onset forms of the disorder. However, they do not exclude the possibility that an AD susceptibility allele is located elsewhere in A2M or a nearby gene.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Age Factors
  • Age of Onset
  • Aged
  • Alzheimer Disease / genetics*
  • Alzheimer Disease / physiopathology
  • Apolipoproteins E / metabolism
  • Female
  • Humans
  • Linkage Disequilibrium / genetics
  • Male
  • Sex Factors
  • alpha-Macroglobulins / genetics*

Substances

  • Apolipoproteins E
  • alpha-Macroglobulins